FDA approves new labelling for Seroquel in bioplar mania

Alderley Park, UK — 23 July, 2004 -- AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved additional efficacy labelling information based on 12-week data for SEROQUEL (quetiapine), a psychotropic medication indicated for the treatment of acute manic episodes associated with bipolar I disorder. The data 1, part of the large scale effort to examine SEROQUEL's use in bipolar disorder, showed that after 12 weeks, approximately two-thirds of patients receiving SEROQUEL alone experienced significant improvement in manic symptoms and achieved remission .

SEROQUEL is the first medication in its class to include monotherapy safety and efficacy data for acute manic episodes associated with bipolar disorder extending beyond three weeks in its label.

"For patients with bipolar disorder and their clinicians, it's important to know that Seroquel is not only effective in reducing symptoms of acute mania the first few weeks, but is also effective in the subsequent continuation phase, when patients can still have significant symptoms and are still at risk for relapsing," said Jamie Mullen, MD, Senior Director of Clinical Research, AstraZeneca. "These data demonstrate that SEROQUEL treatment alone works early and continues to work through 12 weeks. For patients coping with this illness, this is good news."

SEROQUEL was originally approved by the FDA in January 2004 as a monotherapy and adjunct therapy with lithium or divalproex, for the short-term treatment of acute manic episodes associated with bipolar I disorder. This approval was based on efficacy results following three weeks of treatment. These trials showed SEROQUEL to be well-tolerated and effective in the treatment of manic episodes — excited mental states seen in bipolar disorder that are characterized by impulsive behaviour, racing thoughts, pressured speech, and decreased need for sleep. 1, 2.

SEROQUEL has received

Contact: Rupert Doggett
Shire Health International

Page: 1 2 3

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves EPZICOM
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:

(Date:8/31/2020)... ... August 31, 2020 , ... Want to get moving, ... Palsy Alliance Research Foundation (CPARF) is thrilled to launch its fourth annual STEPtember campaign ... fully virtual challenge, STEPtember meets everyone wherever they are at this moment — encouraging ...
(Date:8/31/2020)... IRVINE, Calif. (PRWEB) , ... August 31, 2020 ... ... providers of business support services to dental groups in the United States, today ... serving the community of Beaumont, CA. , Patients will enjoy convenient hours, ...
(Date:8/31/2020)... ... August 31, 2020 , ... In an effort to give ... is donating 10 percent of each hotel room booked with a special new rate ... & Northwest Indiana (RMHC-CNI) , effective immediately. Donations will be applied to any ...
(Date:8/29/2020)... ... , ... When professor and author Randy Pausch was diagnosed with pancreatic cancer, ... than become melancholic, however, he put together a final lecture in Carnegie Hall in ... a negative situation and turned it into something that inspired millions of people worldwide. ...
(Date:8/28/2020)... ... August 28, 2020 , ... The 15 scholarships ... Lighthouse Health & Wellness mobile app and web-portal. NCPCV received a 2020 grant ... awards grants each year to organizations, such as Destination Imagination, which support and ...
Breaking Medicine News(10 mins):
(Date:8/31/2020)... ... August 31, 2020 , ... ... - a broad-spectrum sanitization, disinfection and deodorization provider - is proud to ... sanitizing and disinfecting services for businesses and residents throughout the area. , Germinator ...
(Date:8/27/2020)... (PRWEB) , ... August 27, 2020 , ... ... coordination software, today announced the successful completion of their 2020 System and Organizational ... as their HITRUST® interim assessment and MARS-E compliance assessment. These achievements reflect their ...
(Date:8/27/2020)... ... , ... Bridge To A Cure Foundation announces the appointment of Henry Friedman, ... who serves on the Board of Directors at The Preston Robert Tisch Brain Tumor ... Internationally recognized, Dr. Friedman is a widely published author of more than 500 peer ...
Breaking Medicine Technology:
Cached News: